Oxbryta
This Cigna drug coverage policy governs coverage determinations for Oxbryta (voxelotor) for treatment of sickle cell disease for Cigna-administered health benefit plans and explains the payer stance after the manufacturer's market withdrawal. It affects prescribers, pharmacy and medical reviewers, and members with sickle cell disease.
Pfizer is voluntarily withdrawing Oxbryta from the market and coverage of Oxbryta will not be approved.
Added criteria for 'patient is currently receiving Oxbryta' and removed concurrent use restriction with crizanlizumab (Adakveo).
Coverage Determination
inv-01: Not Covered — Withdrawal
Coverage determination after Pfizer withdrawal
Includes discontinuation of clinical trials and expanded access programs; providers should monitor patients for adverse events after discontinuation.
Voxelotor (Oxbryta) is considered experimental, investigational, or unproven due to insufficient data establishing safety, efficacy, and improved health outcomes. The policy declares that for sickle cell disease coverage of Oxbryta will not be approved following the manufacturer's voluntary withdrawal of all lots.
Oxbryta (voxelotor) is designated as experimental, investigational, or unproven for sickle cell disease, and the policy states that coverage will not be approved after Pfizer’s voluntary withdrawal of the product.
What Providers and Reviewers Should Do
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.